Opinion|Videos|March 10, 2025
A Primary Care Perspective on Newer-Generation Systemic Therapies
Panelists discuss how primary care awareness of biologics and Janus kinase (JAK) inhibitors for atopic dermatitis (AD) remain limited, with outreach efforts by dermatology groups and industry partners showing mixed success in education. While patients on biologics generally report significant symptom improvement, measured through validated tools like EASI, SCORAD, and patient-reported outcome measures, ongoing efforts are needed to bridge the knowledge gap in primary care settings.
Advertisement
Episodes in this series
Video content above in prompted by the following:
- How would you characterize awareness of systemic treatments like biologics and JAK inhibitors for the treatment of AD among primary care practitioners?
- Are the dermatology community/industry/primary care partners /educational meetings reaching primary care providers?
- Do patients using biologics typically report satisfactory improvement in symptoms?
- How do you quantify/assess such improvements?
Advertisement
Related to this article
Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.
Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.
HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
3
Etavopivat Submitted to FDA After 27% VOC Reduction in Phase 3 SCD Trial
4
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
5